Mark L Unruh1, Brett Larive2, Paul W Eggers3, Amit X Garg4, Jennifer J Gassman2, Fredric O Finkelstein5, Paul L Kimmel6, Glenn M Chertow7. 1. Division of Nephrology, University of New Mexico School of Medicine, Albuquerque, NM, USA. 2. Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA. 3. Kidney and Urology Epidemiology Programs, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 4. Division of Nephrology, Western University, London, ON, Canada. 5. Department of Medicine, Hospital of St. Raphael, Yale University School of Medicine, New Haven, CT, USA. 6. Division of Kidney Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA. 7. Stanford University School of Medicine, Stanford, CA, USA.
Abstract
BACKGROUND:Many patients who receive maintenance hemodialysis experience poor sleep. Uncontrolled studies suggest frequent hemodialysis improves sleep quality, which is a strong motivation for some patients to undertake the treatment. We studied the effects of frequent in-center ('daily') and nocturnal home hemodialysis on self-reported sleep quality in two randomized trials. METHODS: Participants were randomly assigned to frequent (six times per week) or conventional (three times per week) hemodialysis in the Frequent Hemodialysis Network Daily (n = 245) and Nocturnal (n = 87) Trials. We used the Medical Outcomes Study Sleep Problems Index II (SPI II), a validated and reliable instrument in patients with end-stage renal disease, to measure self-reported sleep quality. The SPI II is scored from 0-100, with a higher value indicating poorer quality of sleep. A mean relative decline in SPI II would suggest improved sleep quality. The primary sleep outcome was the change in the SPI II score over 12 months. RESULTS: In the Daily Trial, after adjustment for baseline SPI II, subjects randomized to frequent as compared with conventional in-center hemodialysis experienced a 4.2 [95% confidence interval (CI) 0.4-8.0] point adjusted mean relative decline in SPI II at 4 months and a 2.6 (95% CI -2.3-7.5) point adjusted mean relative decline at 12 months. In the Nocturnal Trial, subjects randomized to frequent nocturnal as compared with conventional home hemodialysis experienced 2.9 (95% CI -3.4-9.3) and 4.5 (95% CI -3.2-12.2) point mean relative declines at Months 4 and 12, respectively. CONCLUSIONS: Although a possible benefit of frequent in-center hemodialysis was observed at 4 months, neither frequent in-center hemodialysis nor home nocturnal hemodialysis demonstrated significant improvements in self-reported sleep quality compared with conventional hemodialysis at 12 months. Published by Oxford University Press on behalf of ERA-EDTA 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND: Many patients who receive maintenance hemodialysis experience poor sleep. Uncontrolled studies suggest frequent hemodialysis improves sleep quality, which is a strong motivation for some patients to undertake the treatment. We studied the effects of frequent in-center ('daily') and nocturnal home hemodialysis on self-reported sleep quality in two randomized trials. METHODS:Participants were randomly assigned to frequent (six times per week) or conventional (three times per week) hemodialysis in the Frequent Hemodialysis Network Daily (n = 245) and Nocturnal (n = 87) Trials. We used the Medical Outcomes Study Sleep Problems Index II (SPI II), a validated and reliable instrument in patients with end-stage renal disease, to measure self-reported sleep quality. The SPI II is scored from 0-100, with a higher value indicating poorer quality of sleep. A mean relative decline in SPI II would suggest improved sleep quality. The primary sleep outcome was the change in the SPI II score over 12 months. RESULTS: In the Daily Trial, after adjustment for baseline SPI II, subjects randomized to frequent as compared with conventional in-center hemodialysis experienced a 4.2 [95% confidence interval (CI) 0.4-8.0] point adjusted mean relative decline in SPI II at 4 months and a 2.6 (95% CI -2.3-7.5) point adjusted mean relative decline at 12 months. In the Nocturnal Trial, subjects randomized to frequent nocturnal as compared with conventional home hemodialysis experienced 2.9 (95% CI -3.4-9.3) and 4.5 (95% CI -3.2-12.2) point mean relative declines at Months 4 and 12, respectively. CONCLUSIONS: Although a possible benefit of frequent in-center hemodialysis was observed at 4 months, neither frequent in-center hemodialysis nor home nocturnal hemodialysis demonstrated significant improvements in self-reported sleep quality compared with conventional hemodialysis at 12 months. Published by Oxford University Press on behalf of ERA-EDTA 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Glenn M Chertow; Nathan W Levin; Gerald J Beck; Thomas A Depner; Paul W Eggers; Jennifer J Gassman; Irina Gorodetskaya; Tom Greene; Sam James; Brett Larive; Robert M Lindsay; Ravindra L Mehta; Brent Miller; Daniel B Ornt; Sanjay Rajagopalan; Anjay Rastogi; Michael V Rocco; Brigitte Schiller; Olga Sergeyeva; Gerald Schulman; George O Ting; Mark L Unruh; Robert A Star; Alan S Kliger Journal: N Engl J Med Date: 2010-11-20 Impact factor: 91.245
Authors: Michael V Rocco; Brett Larive; Paul W Eggers; Gerald J Beck; Glenn M Chertow; Nathan W Levin; Alan S Kliger Journal: Am J Kidney Dis Date: 2010-11-30 Impact factor: 8.860
Authors: Bertrand L Jaber; Brigitte Schiller; John M Burkart; Rachid Daoui; Michael A Kraus; Yoojin Lee; Brent W Miller; Isaac Teitelbaum; Amy W Williams; Fredric O Finkelstein Journal: Clin J Am Soc Nephrol Date: 2011-03-17 Impact factor: 8.237
Authors: Michael V Rocco; Robert S Lockridge; Gerald J Beck; Paul W Eggers; Jennifer J Gassman; Tom Greene; Brett Larive; Christopher T Chan; Glenn M Chertow; Michael Copland; Christopher D Hoy; Robert M Lindsay; Nathan W Levin; Daniel B Ornt; Andreas Pierratos; Mary F Pipkin; Sanjay Rajagopalan; John B Stokes; Mark L Unruh; Robert A Star; Alan S Kliger; A Kliger; P Eggers; J Briggs; T Hostetter; A Narva; R Star; B Augustine; P Mohr; G Beck; Z Fu; J Gassman; T Greene; J Daugirdas; L Hunsicker; B Larive; M Li; J Mackrell; K Wiggins; S Sherer; B Weiss; S Rajagopalan; J Sanz; S Dellagrottaglie; M Kariisa; T Tran; J West; M Unruh; R Keene; J Schlarb; C Chan; M McGrath-Chong; R Frome; H Higgins; S Ke; O Mandaci; C Owens; C Snell; G Eknoyan; L Appel; A Cheung; A Derse; C Kramer; N Geller; R Grimm; L Henderson; S Prichard; E Roecker; M Rocco; B Miller; J Riley; R Schuessler; R Lockridge; M Pipkin; C Peterson; C Hoy; A Fensterer; D Steigerwald; J Stokes; D Somers; A Hilkin; K Lilli; W Wallace; B Franzwa; E Waterman; C Chan; M McGrath-Chong; M Copland; A Levin; L Sioson; E Cabezon; S Kwan; D Roger; R Lindsay; R Suri; J Champagne; R Bullas; A Garg; A Mazzorato; E Spanner; M Rocco; J Burkart; S Moossavi; V Mauck; T Kaufman; A Pierratos; W Chan; K Regozo; S Kwok Journal: Kidney Int Date: 2011-07-20 Impact factor: 10.612
Authors: Mark Unruh; Manjula Kurella Tamura; Brett Larive; Anjay Rastogi; Sam James; Brigitte Schiller; Jennifer Gassman; Christopher Chan; Robert Lockridge; Alan Kliger Journal: Am J Nephrol Date: 2011-04-08 Impact factor: 3.754
Authors: Mark L Unruh; Brett Larive; Glenn M Chertow; Paul W Eggers; Amit X Garg; Jennifer Gassman; Maria Tarallo; Fredric O Finkelstein; Paul L Kimmel Journal: Am J Kidney Dis Date: 2013-01-15 Impact factor: 8.860
Authors: Mark L Unruh; Mark H Sanders; Susan Redline; Beth M Piraino; Jason G Umans; Hassan Chami; Rohit Budhiraja; Naresh M Punjabi; Daniel Buysse; Anne B Newman Journal: Am J Kidney Dis Date: 2008-07-09 Impact factor: 8.860
Authors: Ludimila D'Avila E Silva Allemand; Otávio Toledo Nóbrega; Juliane Pena Lauar; Joel Paulo Russomano Veiga; Einstein Francisco Camargos Journal: Int J Nephrol Date: 2017-08-17